You will be redirected to:

Continue
Logo - Kls
Logo - Kls
  • Playbook
  • Services
    Services
    Delivery models
  • Insights
  • Technology
  • Careers
  • About us
    Company purpose
    Life science innovation
    Committed Keyrus
    Regulatory compliance
    Investors
    Management team
    Keyrus Group
    Locations

Efficiently conducting a worldwide phase 2 clinical study with multiple partners

100%

Timeline compliance (submissions, FPFV, CSR, ...)

225 patients

Recruitment target achieved!

Background

Wishing to evaluate the efficacy of a treatment for Non-Alcoholic Steatohepatitis (NASH), this client, a French biopharmaceutical company, entrusted us with this full-service Phase II study, for which the results were highly anticipated and had a major interest for the investors

Challenge

Various challenges were inherent in this study: 1. Complexity of the Study: 71 centers, 3 continents, 3 central labs, standardization of procedures 2. Compliance with the regulations of the 16 countries 3. Difficulty in recruiting patients (requirement for biopsy history and centralized review) 4. Pandemic: Lockdown impacting monitoring activities during database lock 5. Data cleaning & Intermediate analyses (for presentation to investors) involving very tight timelines

Approach

An adapted response has been put in place to meet each challenge: 1. Study team organized around an overall Project Manager and several Study Coordinators 2. Global regulatory management through local contacts/relays 3. Close follow-up of the patient recruitment with implementation of booster calls, protocol amendments (simplification of inclusion/exclusion criteria), and extension to new centers and countries 4. Prompt adaptation of the Monitoring plan, allowing the use of videoconferencing during the lockdown, to maintain the database cleaning delays 5. Anticipation: data cleaning by batch allowing to respect the schedule

Key results

01
Excellent synchronization of the activities carried out on the 3 continents: respect for timelines and the expected level of quality
02
Target recruitment of 225 patients achieved, despite restrictive inclusion/exclusion criteria and numerous competing studies
03
Efficient adaptation to the lockdown: advisory role (operational & regulatory) to the sponsor on actions to be implemented, and justifications to authorities.

Benefits

This Phase II study has been a success, thanks to its good management in full-service: the patient recruitment objective has been reached within the timelines, and with a sufficient quality for statistical analysis. And this despite the pandemic and its lockdown, as well as the multi-continental dimension. The sponsor is satisfied and has been able to communicate in due time to its investors.

Technology partners

Ennov Clinical

Share this key play

whatsapptwitter
linkedinfacebookworkplace

Ready for your own success story?

Get in touch with our team of experts.



I acknowledge having read the privacy policy.

Keyrus collects and processes the data you fill out in this form in order to respond to your request and for commercial prospecting purposes. The fields marked with an asterisk must be filled in for your request to be processed. To learn more about how we manage your personal data and to exercise your rights, please refer to the Privacy Policy. By clicking on Submit, I acknowledge that I have read and accepted the legal notice and the general terms of use of the site.

More key plays

Adapting service platforms (FSP) functionning to fit the client's new outsourcing strategy
Facilitate the provision of an innovative treatment thanks to a Managed Access Program (MAP)
Achieving an end-to-end audit approval from Health Canada
Facilitate data mapping to SDTM by leveraging standardisation and A.I.
Speed up the development of clinical study documents
Transforming pediatric care through digital enablement
Medical device approved for Hearing Loss
Piloting through a pivotal study in cataract eye surgery helping patients recover their vision
Managing efficiently a large cohort RWE study, thanks to dedicated apparatus
Logo - Kls
Headquarters

155 rue Anatole France 92593 Levallois-Perret

Phone:+33 (0)1 41 34 10 00

Fax:+33 (0)1 41 34 10 10

LinkedInKlsInstagram
PlaybookServicesInsightsTechnologyCareersAbout us
Company purposeLife science innovationCommitted KeyrusRegulatory complianceInvestorsManagement teamKeyrus GroupLocations
Legal notice & Terms of use
Privacy policy
Data protection